Evidence map›Paper›PMID 32150561›Full record

ArticlePloS one2020

The epidemiology of Hepatitis B, C and D in Germany: A scoping review.

Gyde Steffen, Ida Sperle, Siv Aina Leendertz, Navina Sarma, Sandra Beermann, Roma Thamm, Viviane Bremer, Ruth Zimmermann, Sandra Dudareva

Open access · goldAbstract readScoping Review
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. [HIV/HCV Among Drug Users in Germany: Elimination Targets in the Mirror of Practice].Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) · 2023
    Article
  11. Article
  12. Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients.Liver international : official journal of the International Association for the Study of the Liver · 2021
    Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Gyde SteffenDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Ida SperleDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Siv Aina LeendertzDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Navina SarmaDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Sandra BeermannDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Roma ThammDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Viviane BremerDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Ruth ZimmermannDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Sandra DudarevaDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Robert Koch Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGermany is considered to be a low prevalence country for viral Hepatitis B, C and D (HBV, HCV, HDV). However, the burden of disease can be high among subpopulations. To meet the world Health Organization (WHO) viral hepatitis (VH) elimination goals, a national strategy was developed by the German government in 2016. We performed a scoping review to understand the baseline epidemiological situation in Germany regarding burden of disease, sequelae and care of HBV, HCV and HDV as a reference to monitor the progress of the national VH elimination and to identify further knowledge gaps and research needs.

methodsThe protocol of the systematic review was prepared following the PRISMA statement guidelines for scoping reviews. Relevant search terms were used to identify eligible studies according to the research questions. We searched six online databases for original work published between January 2005 and March 2017. Based on the identified references, a matrix was developed presenting the eligible literature by targeted population group and outcome category.

results104 publications were eligible for extraction covering 299 outcome results. The population groups targeted in the identified studies included the general population and proxy populations, a range of clinical populations, people who inject drugs, men who have sex with men, healthcare workers, people in prisons and different migrant/mobile populations. Other vulnerable populations (e.g. sex workers) were not targeted. Overall, good evidence was found for HBV and HCV prevalence and HBV vaccination coverage in the GP and proxy populations. Evidence for these outcomes was weaker in populations at risk for VH. For HBV and HCV incidence and mortality, we identified large evidence gaps in all population groups. Outcomes on VH sequelae and care were mainly covered by studies in clinical populations of people living with viral hepatitis. For HDV the overall evidence available was scarce.

conclusionsWe created a comprehensive evidence-based overview on the current epidemiological situation of viral hepatitis in Germany. We identified knowledge gaps for further research and established a baseline for future monitoring of viral hepatitis elimination goals in Germany.

Indexed as

FemaleGermanyHepatitis BHepatitis CHepatitis DHomosexuality, MaleHumansIncidenceMalePrevalenceSexual and Gender MinoritiesSex Workers

Identifiers

PMID32150561
PMCPMC7062254
OpenAlexW3010826753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.